Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more
Sinocelltech Group Ltd (688520) - Total Liabilities
Latest total liabilities as of September 2025: CN¥4.49 Billion CNY
Based on the latest financial reports, Sinocelltech Group Ltd (688520) has total liabilities worth CN¥4.49 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sinocelltech Group Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sinocelltech Group Ltd Competitors by Total Liabilities
The table below lists competitors of Sinocelltech Group Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marfrig Global Foods SA
PINK:MRRTY
|
USA | $122.53 Billion |
|
China Camc Engineering Co Ltd
SHE:002051
|
China | CN¥13.60 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥1.14 Billion |
|
Success Electronics Ltd
SHE:002289
|
China | CN¥201.30 Million |
|
SCG PACKAGING PCL-NVDR
BK:SCGP-R
|
Thailand | ฿92.61 Billion |
|
Shantou Wanshun Package Material
SHE:300057
|
China | CN¥5.39 Billion |
|
Suzhou Kingswood Printing Ink Co Ltd
SHE:300192
|
China | CN¥255.93 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Sinocelltech Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinocelltech Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual total liabilities of Sinocelltech Group Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.15 Billion | -5.27% |
| 2023-12-31 | CN¥3.32 Billion | +11.63% |
| 2022-12-31 | CN¥2.98 Billion | +85.64% |
| 2021-12-31 | CN¥1.60 Billion | +49.21% |
| 2020-12-31 | CN¥1.08 Billion | +39.02% |
| 2019-12-31 | CN¥773.39 Million | +37.22% |
| 2018-12-31 | CN¥563.60 Million | +76.62% |
| 2017-12-31 | CN¥319.10 Million | -6.50% |
| 2016-12-31 | CN¥341.30 Million | -- |